Stay updated on iSCORE Immunotherapy Sequencing Clinical Trial
Sign up to get notified when there's something new on the iSCORE Immunotherapy Sequencing Clinical Trial page.

Latest updates to the iSCORE Immunotherapy Sequencing Clinical Trial page
- ChecktodayChange DetectedThe site revision identifier changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe iSCORE study record for metastatic colorectal cancer is now displayed instead of an access-denied page, with details about the Nivolumab and Relatlimab trial, participant eligibility, and study outcomes.SummaryDifference46%

- Check21 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.3%

- Check28 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The page content below remains a 403 error.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check42 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

Stay in the know with updates to iSCORE Immunotherapy Sequencing Clinical Trial
Enter your email address, and we'll notify you when there's something new on the iSCORE Immunotherapy Sequencing Clinical Trial page.